6.47

0.31% -0.02

After Hours: 6.47

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $6.47, with a volume of 999.57K. It is down -0.31% in the last 24 hours and up +6.59% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$6.49

Open:

$6.56

24h Volume:

999.57K

Relative Volume:

0.44

Market Cap:

$658.32M

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-22.31

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

+0.23%

1M Performance:

+6.59%

6M Performance:

+133.57%

1Y Performance:

+128.62%

1-Day Range:

$6.43

$6.64

1-Week Range:

$6.115

$6.78

52-Week Range:

$2.30

$7.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (670)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	6.47	656.76M	0	-29.07M	-31.85M	-0.29
ONC Beigene Ltd Adr	236.86	24.29B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	447.18	110.94B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.2996	45.05M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	614.79	61.99B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	74.73	5.75B	0	-153.72M	-103.81M	-2.00

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

09:35 AM

Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $2 - GuruFocus

09:35 AM

08:05 AM

Trevi Therapeutics, Inc. Announces Additional Analyses from Phase 2A River Trial of Haduvio in Patients with Refractory Chronic Cough - marketscreener.com

08:05 AM

07:47 AM

Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIV - GuruFocus

07:47 AM

07:20 AM

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough | TRVI Stock News - GuruFocus

07:20 AM

07:17 AM

Raymond James sets $29 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria

07:17 AM

07:11 AM

Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough - marketscreener.com

07:11 AM

07:00 AM

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PR Newswire

07:00 AM

May 19, 2025

Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

May 19, 2025

Price T Rowe Associates Inc. MD Has $104,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 19, 2025

May 17, 2025

Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 17, 2025

May 15, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Raymond James Financial Inc. - Defense World

May 15, 2025

May 14, 2025

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? - Yahoo Finance

May 14, 2025

May 13, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

May 11, 2025

Wells Fargo & Company MN Buys 9,562 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 11, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha

May 11, 2025

May 09, 2025

Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks

May 09, 2025

MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 09, 2025